IVD in cardiology and neurology Market Size, Share and Growth Outlook 2026: By Product Type (Instruments, Reagents and Consumables, Software and Services), By Technology, By End-User, Companies to 2034.
The global IVD in cardiology and neurology market size is forecast to increase from $21.55 Billion in 2026 to $43.83 Billion in 2034 at a CAGR of 9.28% between 2026 and 2034.
The IVD in cardiology and neurology market report provides detailed analysis and outlook of IVD in cardiology and neurology segments including Product Type, Instruments, Reagents and Consumables, Software and Services, Technology, Immunoassays, Molecular Diagnostics, Hematology, Others, End-User, Hospitals and Clinics, Diagnostic Laboratories, Other Healthcare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
IVD in Cardiology and Neurology Industry Overview
Advanced Diagnostics Support Earlier Disease Detection and Monitoring
The IVD in Cardiology and Neurology Industry is experiencing rapid growth as healthcare systems increasingly prioritize early disease detection, continuous monitoring, and personalized treatment strategies for cardiovascular and neurological disorders. Rising prevalence of arrhythmias, heart failure, Alzheimer's disease, neurodegenerative conditions, and other chronic disorders is driving demand for advanced diagnostic technologies capable of delivering accurate and timely clinical insights. The industry is increasingly characterized by the convergence of biomarker testing, digital diagnostics, imaging technologies, and continuous patient monitoring systems. These innovations are helping clinicians identify disease earlier, improve patient stratification, and support more effective long-term disease management.
Cardiac Monitoring Technologies Deliver Greater Diagnostic Accuracy
One of the most significant trends in the cardiology diagnostics segment is the advancement of continuous monitoring technologies. Abbott strengthened its position through the launch of the next-generation Confirm Rx™ Insertable Cardiac Monitor, incorporating SharpSense™ technology designed to reduce false arrhythmia detections by 97%. Improved signal interpretation and continuous 24-hour monitoring capabilities enable more accurate identification of cardiac rhythm abnormalities while reducing unnecessary clinical interventions. As healthcare providers increasingly adopt long-term monitoring strategies for patients at risk of arrhythmias, demand is growing for diagnostic devices that combine precision, reliability, and remote monitoring functionality within a single platform.
Alzheimer's Disease Diagnostics Drive Neurology Innovation
Neurology diagnostics are increasingly focused on identifying neurodegenerative diseases at earlier stages when intervention may provide greater clinical benefit. Siemens Healthineers is playing a central role in this transition through its participation in the ACCESS-AD initiative, a major European research program focused on developing and validating new Alzheimer's disease diagnostic technologies. The initiative combines blood-based biomarker development with advanced PET and MRI imaging approaches to support more standardized and accessible Alzheimer's diagnosis. This reflects a broader industry shift toward non-invasive biomarkers and integrated diagnostic pathways that enable earlier detection and improved management of neurological disorders.
Integrated Diagnostic Ecosystems Strengthen Chronic Disease Management
The market is also benefiting from increasing adoption of comprehensive diagnostic platforms capable of supporting multiple disease areas. Roche highlighted continued strength within its Diagnostics Division, citing sustained demand for core laboratory and pathology solutions used in chronic disease diagnosis and monitoring. Healthcare providers are increasingly favoring integrated diagnostic ecosystems that connect laboratory testing, pathology analysis, biomarker evaluation, and digital workflow management. These platforms improve operational efficiency while supporting more comprehensive patient assessment across cardiovascular and neurological conditions. As chronic disease management becomes increasingly data-driven, integrated diagnostics are emerging as a central pillar of modern cardiology and neurology care pathways.
IVD in cardiology and neurology Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global IVD in cardiology and neurology market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, GE HealthCare Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Becton, Dickinson and Company. The IVD in cardiology and neurology market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the IVD in cardiology and neurology industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in IVD in cardiology and neurology industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, GE HealthCare Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Becton, Dickinson and Company. The IVD in cardiology and neurology market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US IVD in cardiology and neurology Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the IVD in cardiology and neurology market remains one of the strongest-performing segments in the country.
The US IVD in cardiology and neurology Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US IVD in cardiology and neurology market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across IVD in cardiology and neurology industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian IVD in cardiology and neurology markets
Canada's strong IVD in cardiology and neurology sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian IVD in cardiology and neurology market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany IVD in cardiology and neurology Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest IVD in cardiology and neurology market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of IVD in cardiology and neurology population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany IVD in cardiology and neurology industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the IVD in cardiology and neurology market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support IVD in cardiology and neurology sales through 2034
France IVD in cardiology and neurology companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK IVD in cardiology and neurology Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of IVD in cardiology and neurology distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China IVD in cardiology and neurology Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China IVD in cardiology and neurology market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of IVD in cardiology and neurology industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese IVD in cardiology and neurology industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India IVD in cardiology and neurology Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian IVD in cardiology and neurology market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil IVD in cardiology and neurology market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa IVD in cardiology and neurology Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
IVD in cardiology and neurology Market Segmentation
Product Type
Instruments
Reagents and Consumables
Software and Services
Technology
Immunoassays
Molecular Diagnostics
Hematology
Others
End-User
Hospitals and Clinics
Diagnostic Laboratories
Other Healthcare Settings
Leading Companies in IVD in cardiology and neurology Industry (2026)
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
Koninklijke Philips N.V.
Bio-Rad Laboratories, Inc.
QuidelOrtho Corporation
Becton, Dickinson and Company
Countries Included
The IVD in cardiology and neurology market report provides detailed analysis and outlook of IVD in cardiology and neurology segments including Product Type, Instruments, Reagents and Consumables, Software and Services, Technology, Immunoassays, Molecular Diagnostics, Hematology, Others, End-User, Hospitals and Clinics, Diagnostic Laboratories, Other Healthcare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
IVD in Cardiology and Neurology Industry Overview
Advanced Diagnostics Support Earlier Disease Detection and Monitoring
The IVD in Cardiology and Neurology Industry is experiencing rapid growth as healthcare systems increasingly prioritize early disease detection, continuous monitoring, and personalized treatment strategies for cardiovascular and neurological disorders. Rising prevalence of arrhythmias, heart failure, Alzheimer's disease, neurodegenerative conditions, and other chronic disorders is driving demand for advanced diagnostic technologies capable of delivering accurate and timely clinical insights. The industry is increasingly characterized by the convergence of biomarker testing, digital diagnostics, imaging technologies, and continuous patient monitoring systems. These innovations are helping clinicians identify disease earlier, improve patient stratification, and support more effective long-term disease management.
Cardiac Monitoring Technologies Deliver Greater Diagnostic Accuracy
One of the most significant trends in the cardiology diagnostics segment is the advancement of continuous monitoring technologies. Abbott strengthened its position through the launch of the next-generation Confirm Rx™ Insertable Cardiac Monitor, incorporating SharpSense™ technology designed to reduce false arrhythmia detections by 97%. Improved signal interpretation and continuous 24-hour monitoring capabilities enable more accurate identification of cardiac rhythm abnormalities while reducing unnecessary clinical interventions. As healthcare providers increasingly adopt long-term monitoring strategies for patients at risk of arrhythmias, demand is growing for diagnostic devices that combine precision, reliability, and remote monitoring functionality within a single platform.
Alzheimer's Disease Diagnostics Drive Neurology Innovation
Neurology diagnostics are increasingly focused on identifying neurodegenerative diseases at earlier stages when intervention may provide greater clinical benefit. Siemens Healthineers is playing a central role in this transition through its participation in the ACCESS-AD initiative, a major European research program focused on developing and validating new Alzheimer's disease diagnostic technologies. The initiative combines blood-based biomarker development with advanced PET and MRI imaging approaches to support more standardized and accessible Alzheimer's diagnosis. This reflects a broader industry shift toward non-invasive biomarkers and integrated diagnostic pathways that enable earlier detection and improved management of neurological disorders.
Integrated Diagnostic Ecosystems Strengthen Chronic Disease Management
The market is also benefiting from increasing adoption of comprehensive diagnostic platforms capable of supporting multiple disease areas. Roche highlighted continued strength within its Diagnostics Division, citing sustained demand for core laboratory and pathology solutions used in chronic disease diagnosis and monitoring. Healthcare providers are increasingly favoring integrated diagnostic ecosystems that connect laboratory testing, pathology analysis, biomarker evaluation, and digital workflow management. These platforms improve operational efficiency while supporting more comprehensive patient assessment across cardiovascular and neurological conditions. As chronic disease management becomes increasingly data-driven, integrated diagnostics are emerging as a central pillar of modern cardiology and neurology care pathways.
IVD in cardiology and neurology Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global IVD in cardiology and neurology market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, GE HealthCare Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Becton, Dickinson and Company. The IVD in cardiology and neurology market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the IVD in cardiology and neurology industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth IVD in cardiology and neurology Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by IVD in cardiology and neurology companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional IVD in cardiology and neurology markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in IVD in cardiology and neurology industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, GE HealthCare Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Becton, Dickinson and Company. The IVD in cardiology and neurology market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US IVD in cardiology and neurology Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the IVD in cardiology and neurology market remains one of the strongest-performing segments in the country.
The US IVD in cardiology and neurology Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US IVD in cardiology and neurology market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across IVD in cardiology and neurology industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian IVD in cardiology and neurology markets
Canada's strong IVD in cardiology and neurology sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian IVD in cardiology and neurology market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany IVD in cardiology and neurology Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest IVD in cardiology and neurology market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of IVD in cardiology and neurology population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany IVD in cardiology and neurology industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the IVD in cardiology and neurology market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support IVD in cardiology and neurology sales through 2034
France IVD in cardiology and neurology companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK IVD in cardiology and neurology Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of IVD in cardiology and neurology distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China IVD in cardiology and neurology Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China IVD in cardiology and neurology market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of IVD in cardiology and neurology industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese IVD in cardiology and neurology industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India IVD in cardiology and neurology Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian IVD in cardiology and neurology market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil IVD in cardiology and neurology market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa IVD in cardiology and neurology Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
IVD in cardiology and neurology Market Segmentation
Product Type
Instruments
Reagents and Consumables
Software and Services
Technology
Immunoassays
Molecular Diagnostics
Hematology
Others
End-User
Hospitals and Clinics
Diagnostic Laboratories
Other Healthcare Settings
Leading Companies in IVD in cardiology and neurology Industry (2026)
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
Koninklijke Philips N.V.
Bio-Rad Laboratories, Inc.
QuidelOrtho Corporation
Becton, Dickinson and Company
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential IVD in cardiology and neurology Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the IVD in cardiology and neurology Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL IVD IN CARDIOLOGY AND NEUROLOGY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global IVD in cardiology and neurology Markets in 2026
3.2. Global Historic and Forecast IVD in cardiology and neurology Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key IVD in cardiology and neurology Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential IVD in cardiology and neurology Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across IVD in cardiology and neurology Value Chain
CHAPTER 4- IVD IN CARDIOLOGY AND NEUROLOGY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading IVD in cardiology and neurology Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- IVD IN CARDIOLOGY AND NEUROLOGY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
Product Type
Instruments
Reagents and Consumables
Software and Services
Technology
Immunoassays
Molecular Diagnostics
Hematology
Others
End-User
Hospitals and Clinics
Diagnostic Laboratories
Other Healthcare Settings
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America IVD in cardiology and neurology Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
7.5. North America IVD in cardiology and neurology Market Size Outlook by Type
7.6. North America IVD in cardiology and neurology Market Size Outlook by Application
7.7. North America IVD in cardiology and neurology Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US IVD in cardiology and neurology Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada IVD in cardiology and neurology Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico IVD in cardiology and neurology Companies
CHAPTER 8- EUROPE IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe IVD in cardiology and neurology Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
8.5. Europe IVD in cardiology and neurology Market Size Outlook by Type
8.6. Europe IVD in cardiology and neurology Market Size Outlook by Application
8.7. Europe IVD in cardiology and neurology Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany IVD in cardiology and neurology Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France IVD in cardiology and neurology Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK IVD in cardiology and neurology Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain IVD in cardiology and neurology Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy IVD in cardiology and neurology Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe IVD in cardiology and neurology Companies
CHAPTER 9- ASIA PACIFIC IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific IVD in cardiology and neurology Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Type
9.6. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Application
9.7. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China IVD in cardiology and neurology Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan IVD in cardiology and neurology Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India IVD in cardiology and neurology Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea IVD in cardiology and neurology Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia IVD in cardiology and neurology Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia IVD in cardiology and neurology Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America IVD in cardiology and neurology Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
10.5. South and Central America IVD in cardiology and neurology Market Size Outlook by Type
10.6. South and Central America IVD in cardiology and neurology Market Size Outlook by Application
10.7. South and Central America IVD in cardiology and neurology Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil IVD in cardiology and neurology Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina IVD in cardiology and neurology Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America IVD in cardiology and neurology Companies
CHAPTER 11- MIDDLE EAST AND AFRICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa IVD in cardiology and neurology Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Type
11.6. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Application
11.7. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia IVD in cardiology and neurology Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE IVD in cardiology and neurology Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa IVD in cardiology and neurology Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in IVD in cardiology and neurology Industry
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
Koninklijke Philips N.V.
Bio-Rad Laboratories, Inc.
QuidelOrtho Corporation
Becton, Dickinson and Company
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential IVD in cardiology and neurology Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the IVD in cardiology and neurology Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL IVD IN CARDIOLOGY AND NEUROLOGY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global IVD in cardiology and neurology Markets in 2026
3.2. Global Historic and Forecast IVD in cardiology and neurology Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key IVD in cardiology and neurology Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential IVD in cardiology and neurology Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across IVD in cardiology and neurology Value Chain
CHAPTER 4- IVD IN CARDIOLOGY AND NEUROLOGY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading IVD in cardiology and neurology Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- IVD IN CARDIOLOGY AND NEUROLOGY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
Product Type
Instruments
Reagents and Consumables
Software and Services
Technology
Immunoassays
Molecular Diagnostics
Hematology
Others
End-User
Hospitals and Clinics
Diagnostic Laboratories
Other Healthcare Settings
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America IVD in cardiology and neurology Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
7.5. North America IVD in cardiology and neurology Market Size Outlook by Type
7.6. North America IVD in cardiology and neurology Market Size Outlook by Application
7.7. North America IVD in cardiology and neurology Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US IVD in cardiology and neurology Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada IVD in cardiology and neurology Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico IVD in cardiology and neurology Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico IVD in cardiology and neurology Companies
CHAPTER 8- EUROPE IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe IVD in cardiology and neurology Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
8.5. Europe IVD in cardiology and neurology Market Size Outlook by Type
8.6. Europe IVD in cardiology and neurology Market Size Outlook by Application
8.7. Europe IVD in cardiology and neurology Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany IVD in cardiology and neurology Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France IVD in cardiology and neurology Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK IVD in cardiology and neurology Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain IVD in cardiology and neurology Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy IVD in cardiology and neurology Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe IVD in cardiology and neurology Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe IVD in cardiology and neurology Companies
CHAPTER 9- ASIA PACIFIC IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific IVD in cardiology and neurology Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Type
9.6. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Application
9.7. Asia Pacific IVD in cardiology and neurology Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China IVD in cardiology and neurology Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan IVD in cardiology and neurology Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India IVD in cardiology and neurology Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea IVD in cardiology and neurology Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia IVD in cardiology and neurology Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia IVD in cardiology and neurology Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America IVD in cardiology and neurology Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
10.5. South and Central America IVD in cardiology and neurology Market Size Outlook by Type
10.6. South and Central America IVD in cardiology and neurology Market Size Outlook by Application
10.7. South and Central America IVD in cardiology and neurology Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil IVD in cardiology and neurology Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina IVD in cardiology and neurology Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America IVD in cardiology and neurology Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America IVD in cardiology and neurology Companies
CHAPTER 11- MIDDLE EAST AND AFRICA IVD IN CARDIOLOGY AND NEUROLOGY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa IVD in cardiology and neurology Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa IVD in cardiology and neurology Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Type
11.6. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Application
11.7. Middle East and Africa IVD in cardiology and neurology Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia IVD in cardiology and neurology Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE IVD in cardiology and neurology Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa IVD in cardiology and neurology Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa IVD in cardiology and neurology Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in IVD in cardiology and neurology Industry
F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
Koninklijke Philips N.V.
Bio-Rad Laboratories, Inc.
QuidelOrtho Corporation
Becton, Dickinson and Company
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
